TickerFacts.

Company research / ROIV

Roivant Sciences Ltd. (ROIV)

Build a valuation ↗↓ Download CSV

CIK 0001635088 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Mar 31

For the year ended 2026-03-31, Roivant Sciences Ltd. reported revenue of $8.26M. Revenue fell 71.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $7.53M.

Key ratios (year ended 2026-03-31)

n/m
Operating margin
n/m
Net margin
-6.6%
Return on year-end equity
-71.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-31
Revenue$7.53M$8.26M$29.05M$32.71M$31.53M$55.29M$23.80M
R&D Expense$730.91M$681.81M$550.41M$439.91M$454.06M$483.04M$236.63M
Operating Income-$596.14M-$515.07M-$1.00B$4.50B-$906.76M-$1.35B-$1.07B
Depreciation & Amortization$2.85M$3.35M$14.07M$22.04M$18.86M$5.93Mn/a
EBITDA-$593.29M-$511.72M-$989.22M$4.52B-$887.91M-$1.35Bn/a
Net Income-$266.25M-$299.77M-$171.98M$4.35B-$1.01B-$845.26M-$809.23M
EPS (Diluted)n/a-$0.54-$0.24$5.23-$1.42-$1.26n/a
Total Assets$5.31B$5.71B$5.44B$7.22B$2.39B$2.59B$2.59B
Total Liabilities$384.62M$416.27M$249.74M$773.95M$782.02M$523.70M$527.69M
Long-Term Debtn/an/an/a$430.59M$375.51M$210.03M$170.28M
Shareholders' Equity$4.23B$4.53B$4.69B$5.97B$1.16B$1.66B$1.80B
Cash & Equivalents$1.25B$1.42B$2.72B$6.49B$1.68B$2.06B$2.06B
Operating Cash Flow-$816.47M-$750.35M-$839.45M-$765.27M-$843.39M-$677.73M-$552.14M
Capital Expenditures$4.59M$8.21M$4.60M$1.38M$12.69M$17.44M$5.81M
Free Cash Flow-$821.06M-$758.56M-$844.05M-$766.65M-$856.08M-$695.16M-$557.94M
Share Repurchasesn/an/a$1.29B$0$0n/an/a
Shares Outstanding722.67M720.35M695.94M806.68M760.14M694.98M651.58M
Weighted Average Diluted Sharesn/a693.86M725.40M831.05M712.79M669.75Mn/a
EPS (Basic)n/a-$0.43-$0.24$5.55-$1.42-$1.26n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView